Search
Search Results
##search.searchResults.foundPlural##
-
RELIABILITY OF DIFFERENT RBC INDICES AND FORMULAS IN DISCRIMINATING BETWEEN ?-THALASSEMIA MINOR AND OTHER CAUSES OF MICROCYTIC HYPOCHROMIC ANEMIA
3071PDF: 1663HTML: 14668Untitled: 233Untitled: 195 -
STUDY OF SERUM HAPTOGLOBIN LEVEL AND ITS RELATION TO ERYTHROPOIETIC ACTIVITY IN BETA THALASSEMIA CHILDREN .
2319PDF: 1198HTML: 2605Study of serum haptoglobin level in thalassemia: 382Figures: 210 -
GENETIC HETEROGENEITY OF BETA GLOBIN MUTATIONS AMONG ASIAN-INDIANS AND IMPORTANCE IN GENETIC COUNSELLING AND DIAGNOSIS
1881PDF: 1324HTML: 11572Figure1: 192Figure 2: 199 -
HEMOGLOBIN ANALYSIS IN THE FIRST YEAR OF LIFE
3591PDF: 1079HTML: 3072 -
AGING WITH THALASSEMIA AND SICKLE CELL DISEASE: A GERONTOLOGICAL MODEL OF ACCELERATED MULTIMORBIDITY AND FUNCTION-CENTERED CARE BEYOND MIDLIFE Thalassemia and Sickle Cell Diseases: Effect of Aging
497PDF: 526Suppl. Files: 66HTML: 153 -
VASCULAR ENDOTHELIAL GROWTH FACTOR IN CHILDREN WITH THALASSEMIA MAJOR PDF
1389PDF: 897HTML: 1106Figure 1 the correlation between frequency of blood transfusion and serum vascular endothelial growth factor (VEGF).: 207 -
A MULTICENTER ICET-A SURVEY ON ADHERENCE TO ANNUAL ORAL GLUCOSE TOLERANCE TEST (OGTT) SCREENING IN TRANSFUSION-DEPENDENT THALASSEMIA (TDT) PATIENTS - THE EXPERT CLINICIANS’ OPINION ON FACTORS INFLUENCING THE ADHERENCE AND ON ALTERNATIVE STRATEGIES FOR ADHERENCE OPTIMIZATION Survey on adherence to annual OGTT in thalassemia
2993PDF: 1379HTML: 167 -
QUALITY OF LIFE IN PATIENTS WITH THALASSEMIA MAJOR AND INTERMEDIA IN KERMAN-IRAN (I.R.)
1730PDF: 802HTML: 2394Cover Letter: 210 -
THE PERFORMANCE OF HOMA 2 COMPARED TO DYNAMIC MARKERS OF INSULIN SECRETION AND SENSITIVITY/RESISTANCE FOR PREDICTING DYSGLYCEMIA IN TRANSFUSION-DEPENDENT Β-THALASSEMIA: THE EXPERIENCE OF A SINGLE CENTRE HOMA 2 and DYNAMIC MARKERS OF INSULIN SECRETION FOR PREDICTING DYSGLYCEMIA in TDT
182PDF: 175HTML: 45 -
EXERCISE STRESS ECHOCARDIOGRAPHY WITH TISSUE DOPPLER IMAGING (TDI) DETECTS EARLY SYSTOLIC DYSFUNCTION IN BETA-THALASSEMIA MAJOR PATIENTS WITHOUT CARDIAC IRON OVERLOAD
1396PDF: 839HTML: 7887Manuscript after revision: 262Barbero10328-36310-after revision: 256 -
THERAPEUTIC VALUE OF COMBINED THERAPY WITH DEFERASIROX AND SILYMARIN ON IRON OVERLOAD IN CHILDREN WITH BETA THALASSEMIA
2798PDF: 863HTML: 15024Therapeutic Value of Combined Therapy with Deferasirox and Silymarin on Iron Overload in Children with Beta Thalassemia: 339 -
-
GLUCOSE METABOLISM AND INSULIN RESPONSE TO ORAL GLUCOSE TOLERANCE TEST (OGTT) IN PREPUBERTAL PATIENTS WITH TRANSFUSION DEPENDENT Β-THALASSEMIA (TDT): A LONG-TERM RETROSPECTIVE ANALYSIS Long-term retrospective analysis of glucose homeostasis in children with transfusion dependent β-thalassemia
1868PDF: 584HTML: 247 -
-
-
COMPARATIVE STUDY ON THE MEASUREMENT OF LIVER T2* VALUES OF THALASSEMIA PATIENTS AND THE CLINICAL GRADING OF LIVER IRON CONCENTRATION BY DIFFERENT POST-PROCESSING SOFTWARE MEASUREMENT OF LIVER T2* VALUES OF THALASSEMIA
2269PDF: 645HTML: 326 -
-
COAGULOPATHY IN BETA-THALASSEMIA: CURRENT UNDERSTANDING AND FUTURE PERSPECTIVES
1226PDF: 504HTML: 8263 -
Identification of Alpha Thalassemia, RNF 213 p.R4810K and PROC p.R189W among Children with Moyamoya Disease/Syndrome Alpha Thalassemia and RNF 213 Gene Mutation in Moyamoya
1028PDF: 767HTML: 254 -
VITAMIN D STATUS IN THALASSEMIA MAJOR: AN UPDATE
2823PDF: 1114HTML: 2620 -
THERAPEUTIC GENE EDITING FOR HEMOGLOBINOPATHIES Gene therapy for Hemoglobinopathies.
2283PDF: 1358Html: 341 -
Concordance Rate of Fasting Plasma Glucose (PG) and 2-hour PG post Oral Glucose Tolerance Test (OGTT) in Patients with new diagnosis of Thalassemia-Related Diabetes Mellitus (Th-RDM):Implications for Clinical Practice OGTT concordance rate in thalassemia major
768PDF: 584Html: 138 -
-
JUSTIFICATION OF UNIVERSAL IRON SUPPLEMENTATION FOR INFANTS 6-12 MONTHS IN REGIONS WITH A HIGH PREVALENCE OF THALASSEMIA Iron Supplementation for Infants 6-12 months in Regions with a High Prevalence of Thalassemia
3234PDF: 642Suppl. Files: 301HTML: 275 -
PREVENTION OF ? THALASSEMIA IN NORTHERN ISRAEL - A COST-BENEFIT ANALYSIS.
3154PDF: 1304HTML: 11859 -
END-OF-LIFE CARE IN SICKLE CELL DISEASE AND TRASFUSION DEPENDEND-β-THALASSEMIA: CLINICAL, PSYCHOLOGICAL, AND ETHICAL CONSIDERATION Challenges in Supportive Care, Equity, and Compassion at End of Life
1197PDF: 846Html: 190







